0001209191-22-024290.txt : 20220413 0001209191-22-024290.hdr.sgml : 20220413 20220413163615 ACCESSION NUMBER: 0001209191-22-024290 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220411 FILED AS OF DATE: 20220413 DATE AS OF CHANGE: 20220413 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lachey Jennifer CENTRAL INDEX KEY: 0001808322 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 22825064 MAIL ADDRESS: STREET 1: C/O KEROS THERAPEUTICS, INC. STREET 2: 99 HAYDEN AVENUE, SUITE 120, BUILDING E CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-513-8774 MAIL ADDRESS: STREET 1: 99 HAYDEN AVENUE, SUITE 120 (BLD E) STREET 2: LEDGEMONT TECHNOLOGY CENTER CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-04-11 0 0001664710 Keros Therapeutics, Inc. KROS 0001808322 Lachey Jennifer C/O KEROS THERAPEUTICS, INC. 99 HAYDEN AVENUE, SUITE 120, BUILDING E LEXINGTON MA 02421 0 1 0 0 Chief Scientific Officer Common Stock 2022-04-11 4 M 0 5300 0.30 A 91000 D Common Stock 2022-04-11 4 S 0 1417 61.37 D 89583 D Common Stock 2022-04-11 4 S 0 1009 62.32 D 88574 D Common Stock 2022-04-11 4 S 0 2315 63.50 D 86259 D Common Stock 2022-04-11 4 S 0 559 64.15 D 85700 D Employee Stock Option (right to buy) 0.30 2022-04-11 4 M 0 5300 0.00 D 2028-03-25 Common Stock 5300 71405 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.97 to $61.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.975 to $62.97 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.975 to $63.865 inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.49 inclusive. Immediately exercisable. /s/ Keith Regnante, Attorney-in-Fact 2022-04-13